More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

Abzena, a CDMO, said it has expanded its early- and late-phase analytical capabilities to now include GMP cell-based potency assays at their Cambridge, U.K., and San Diego, CA, development and ...

The companies will work together through the process development, preclinical assessment and initial trials of TCR therapies.

In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. At the 4th Cell Therapy Potency Assay Summit, we will unite analytical development ...

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of such treatment, with Rafael E Carazo Salas ...

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies.